NCT00193557

Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

Phase I Trial of Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (planned)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase I study will evaluate the feasibility and toxicity of weekly bortezomib in the treatment of relapsed or refractory multiple Myeloma and determine whether a twice-weekly schedule of bortezomib is effective in producing responses in patients with stable disease or progression after weekly bortezomib

Detailed description

Upon determination of eligibility, patients will be receive: * Bortezomib

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Bortezomib

Timeline

• Start date: 2004-05-01
• Primary completion: 2006-05-01
• Completion: 2009-01-01
• First posted: 2005-09-19
• Last updated: 2010-06-29

Locations

2 sites across 1 country: United States